Combined regimen of temozolomide and liposomal pegylated doxorubicin in glioblastoma - Toxicity and efficacy

被引：0
|
作者：
Hau, P
Jauch, T
Steinbrecher, A
Bogdahn, U
机构：
来源：
NEUROLOGY | 2006年 / 66卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：A336 / A336
页数：1
相关论文
共 50 条
  • [11] Efficacy and toxicity profile of pegylated liposomal doxorubicin in patients with advanced ovarian cancer
    Mayer, Christine
    Brucker, Janina
    Schuetz, Florian
    Domschke, Christoph
    Bechstein, Sarah
    Heil, Joerg
    Golatta, Michael
    Wallwiener, Markus
    Sohn, Christof
    Schneeweiss, Andreas
    Rom, Joachim
    [J]. ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2016, 294 (01) : 123 - 129
  • [12] A metanalysis of the efficacy and safety of pegylated liposomal doxorubicin
    Castellanos-Toledo, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [13] Direct comparison of two pegylated liposomal doxorubicin formulations: Is AUC predictive for toxicity and efficacy?
    Cui, JingXia
    Li, ChunLei
    Guo, WenMin
    Li, YanHui
    Wang, CaiXia
    Zhang, Li
    Zhang, Lan
    Hao, Yanli
    Wang, YongLi
    [J]. JOURNAL OF CONTROLLED RELEASE, 2007, 118 (02) : 204 - 215
  • [14] Efficacy and toxicity profile of pegylated liposomal doxorubicin (Caelyx) in patients with advanced breast cancer
    Rom, Joachim
    Bechstein, Sarah
    Domschke, Christoph
    Golatta, Michael
    Mayer, Christine
    Heil, Joerg
    Thum, Janina
    Smetanay, Katharina
    Windemuth-Kieselbach, Christine
    Wallwiener, Markus
    Marme, Frederik
    Schuetz, Florian
    Sohn, Christof
    Schneeweiss, Andreas
    [J]. ANTI-CANCER DRUGS, 2014, 25 (02) : 219 - 224
  • [15] CARDIOTOXICITY OF COMBINED PEGYLATED LIPOSOMAL DOXORUBICIN AND BEVACIZUMAB THERAPY
    Hoeger, Christopher William
    Diaz, Andrea N. Rosas
    Pinto, Theresa
    Asnani, Aarti
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (08) : 2311 - 2311
  • [16] Phase 2 trial of temozolomide and pegylated liposomal doxorubicin in the treatment of patients with glioblastoma multiforme following concurrent radiotherapy and chemotherapy
    Ananda, Sumitra
    Nowak, Anna K.
    Cher, Lawrence
    Dowling, Anthony
    Brown, Chris
    Simes, John
    Rosenthal, Mark A.
    [J]. JOURNAL OF CLINICAL NEUROSCIENCE, 2011, 18 (11) : 1444 - 1448
  • [17] Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
    Rao N. V. S. Mamidi
    Steve Weng
    Susan Stellar
    Charles Wang
    Ning Yu
    Tony Huang
    Alfred P. Tonelli
    Michael F. Kelley
    Anthony Angiuoli
    Man-Cheong Fung
    [J]. Cancer Chemotherapy and Pharmacology, 2010, 66 : 1173 - 1184
  • [18] Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
    Mamidi, Rao N. V. S.
    Weng, Steve
    Stellar, Susan
    Wang, Charles
    Yu, Ning
    Huang, Tony
    Tonelli, Alfred P.
    Kelley, Michael F.
    Angiuoli, Anthony
    Fung, Man-Cheong
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (06) : 1173 - 1184
  • [19] Efficacy and toxicity of prolonged pegylated liposomal doxorubicin use in women with recurrent epithelial ovarian cancer
    Chambers, Laura M.
    Pendlebury, Adam
    Rose, Peter G.
    Yao, Meng
    DeBernardo, Robert
    [J]. GYNECOLOGIC ONCOLOGY, 2020, 158 (02) : 309 - 315
  • [20] EFFECTIVENESS AND TOXICITY OF PEGYLATED LIPOSOMAL DOXORUBICIN FOR ADVANCED OVARIAN CANCER
    Sequeira, I.
    Simas, A.
    Brandao, M.
    Savva-Bordalo, J.
    Pereira, D.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 1491 - 1491
12345